8-K current report · filed Oct 15, 2026

OPKO HEALTH, INC. (OPK) 8-K Current Report: October 15, 2026

Item 1.01OPK overview

Short answer

OPKO HEALTH, INC. (OPK) filed an 8-K current report with the SEC on October 15, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). OPKO agreed to sell BioReference testing assets to Labcorp for $722 million cash at closing.

OPKO HEALTH, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • OPKO agreed to sell BioReference testing assets to Labcorp for $722 million cash at closing
  • Additional consideration up to $150 million over 10 years tied to 4Kscore prostate test revenue
  • Closing requires HSR antitrust clearance, with no financing condition, supporting transaction funding certainty
  • Target closing deadline April 14, 2027, subject to extension by mutual agreement
  • $28.88 million buyer termination fee if specified regulatory approvals fail

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other OPKO HEALTH, INC. 8-K filings

Get the next OPK 8-K as it lands

Follow OPK for push alerts, or ask the research agent what this filing means.